Drug General Information (ID: DDI5F8SMX3)
Drug Name			Iodide I-123		Drug Info		Acrivastine		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Diagnostic Radiopharmaceuticals				Antiinflammatory Agents
Structure

Mechanism of Iodide I-123-Acrivastine Interaction (Severity Level: Moderate)
Attenuated pharmacological effects (Unspecific) Click to Show/Hide Mechanism Graph
Drug Name		Iodide I-123				Acrivastine
Mechanism		Radioiodide				Interfere with the therapeutic effect and/or diagnostic result of radioiodides
Key Mechanism Factor 1
		Factor Name		Pharmacodynamics
		Factor Description		Reduced pharmacological effects leading to insufficient efficacy and/or treatment failure.
Mechanism Description		Attenuated pharmacological effects of  Iodide I-123 when combined with Acrivastine

Recommended Action
Management		Antithyroid agents such as carbimazole or propylthiouracil should generally be withheld for 1 week before administration of sodium iodide I-131 or I-123, and for a few days afterward. Salicylates, steroids, anticoagulants, antihistamines, antiparasitics, penicillins, sulfonamides, tolbutamide, thiopental, and nitroprusside should generally be withheld for 1 week. Amiodarone, lithium, and benzodiazepines should be withheld for at least 4 weeks.

References
1	Product Information. Rexulti (brexpiprazole). Otsuka American Pharmaceuticals Inc, Rockville, MD.
2	Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
3	Product Information. Sodium Iodide I-123 (sodium iodide I-123). GE Healthcare, Princeton, NJ.